Sandbox vidit5: Difference between revisions

Jump to navigation Jump to search
Line 1: Line 1:
==Management==
==Management==
Shown below is an algorithm summarizing the approach to <nowiki>[[disease name]]</nowiki>.
Shown below is an algorithm summarizing the approach to <nowiki>[[Anaphylaxis]]</nowiki>.


{{familytree/start |summary=PE diagnosis Algorithm.}}
{{familytree/start |summary=PE diagnosis Algorithm.}}
{{familytree | | | | | | | | A01 |A01=<div style="float: left; text-align: left; height: 45 em; width: 45em ">'''Characterize the symptoms & signs:''' <br> Skin, subcutaneous tissue and mucosa: <br> ❑ Flushing, itching, urticaria, angioedema, rash, piloerection <br> ❑ Periorbital itching, erythema and edema; conjunctival erythema, tearing <br>
{{familytree | | | | | | | | A01 |A01=<div style="float: left; text-align: left; height: 30 em; width: 30 em ">'''Characterize the symptoms & signs:''' <br> Skin, subcutaneous tissue and mucosa: <br> ❑ Flushing, itching, urticaria, angioedema, rash, piloerection <br> ❑ Periorbital itching, erythema and edema; conjunctival erythema, tearing <br>
----
----
Respiratory: <br> ❑ Nasal itching, congestion, rhinorrhea, sneezing <br> ❑ Throat itching and tightness, dysphonia, hoarseness, stridor, dry staccato cough <br> ❑ Tachypnea, dyspnea,chest tightness, wheezing/bronchospasm <br> ❑ Cyanosis <br> ❑ Respiratory arrest <br>
Respiratory: <br> ❑ Nasal itching, congestion, rhinorrhea, sneezing <br> ❑ Throat itching and tightness, dysphonia, hoarseness, stridor, dry staccato cough <br> ❑ Tachypnea, dyspnea,chest tightness, wheezing/bronchospasm <br> ❑ Cyanosis <br> ❑ Respiratory arrest <br>
Line 17: Line 17:
{{familytree | | | | | | | | C01 | | | | | |C01=Remove patient from exposure/trigger }}
{{familytree | | | | | | | | C01 | | | | | |C01=Remove patient from exposure/trigger }}
{{familytree | | | | | | | | |!| | | | | | }}
{{familytree | | | | | | | | |!| | | | | | }}
{{familytree | | | | | | | | D01 | | | | | |D01=<div style="float: left; text-align: left">Do all 3 simultaneously <br> ❑ Call for help <br> ❑'''Inject aqueous epinephrine (adrenaline) IM in the mid-anterolateral aspect of the thigh, 0.01 mg/kg of a 1:1,000 (1 mg/mL) solution''' <br>Maximum dose 0.5 mg (adult) or 0.3 mg (child) <br> Record the time of the dose and repeat it in 5-10 minutes, if needed or <br> ❑ In patients with hypotension/cardiorespiratory arrest and those not responding: Intravenous epinephrine <br> 1:100,000 solution of epinephrine (0.1 mg [1 ml of 1:1000] in 100 ml saline) intravenously by infusion pump at an initial rate of 30-100 ml/hr (5-15 mg/min) <br> Titrate based on clinical response or epinephrine side effects <br> ❑ Place patient on back/comfortable position; elevate legs</div> }}
{{familytree | | | | | | | | D01 | | | | | |D01=<div style="float: left; text-align: left">Do all 3 simultaneously <br> ❑ Call for help <br> ❑ '''Inject aqueous epinephrine (adrenaline) IM in the mid-anterolateral aspect of the thigh, 0.01 mg/kg of a 1:1,000 (1 mg/mL) solution''' <br>Maximum dose 0.5 mg (adult) or 0.3 mg (child) <br> Record the time of the dose and repeat it in 5-10 minutes, if needed or <br> ❑ Intravenous epinephrine: In patients with hypotension/cardiorespiratory arrest and those not responding <br>
: 1:100,000 solution of epinephrine (0.1 mg [1 ml of 1:1000] in 100 ml saline) intravenously by infusion pump at an initial rate of 30-100 ml/hr (5-15 mg/min) <br> Titrate based on clinical response or epinephrine side effects <br>
❑ Place patient on back/comfortable position; elevate legs</div> }}
{{familytree | | | | | | | | |!| | | | | | | }}
{{familytree | | | | | | | | |!| | | | | | | }}
{{familytree | | | | E02 |-| E01 | | | | | | | |E01=<div style="float: left; text-align: left"> Patient has one of the following? <br> ❑ Respiratory distress <br> ❑ Recieved repeated doses of epinephrine <br> ❑ Asthma/other respiratory disease <br> ❑ Co-existing cardiovascular disease </div> |E02=Yes}}
{{familytree | | | | E02 |-| E01 | | | | | | | |E01=<div style="float: left; text-align: left"> Patient has one of the following? <br> ❑ Respiratory distress <br> ❑ Recieved repeated doses of epinephrine <br> ❑ Asthma/other respiratory disease <br> ❑ Co-existing cardiovascular disease </div> |E02=Yes}}
Line 27: Line 29:
{{familytree | | | | | | | | H01 | | H02 | | |H01=No |H02=<div style="float: left; text-align: left"> ❑ Establish IV access <br> ❑ Give 1-2 litres of 0.9% saline rapidly, 5-10 ml/Kg in first 5-10 mins <br> ❑  Give vasopressors (dopamine) 400mg in 500ml of 5% dextrose at 2-20 mg/kg/min to maintain a target systolic BP > 90 mm Hg </div> }}
{{familytree | | | | | | | | H01 | | H02 | | |H01=No |H02=<div style="float: left; text-align: left"> ❑ Establish IV access <br> ❑ Give 1-2 litres of 0.9% saline rapidly, 5-10 ml/Kg in first 5-10 mins <br> ❑  Give vasopressors (dopamine) 400mg in 500ml of 5% dextrose at 2-20 mg/kg/min to maintain a target systolic BP > 90 mm Hg </div> }}
{{familytree | | | | | | | | |!| | | |!| | | | }}
{{familytree | | | | | | | | |!| | | |!| | | | }}
{{familytree | | | | | | | | I01 |-|-|'| | | |I01=<div style="float: left; text-align: left"> Secondary therapy after epinephrine (evidence not clear) <br> H1 antihistaminics: <br> ❑ Diphenhydramine IM or slow intravenous infusion - 25 to 50 mg in adults, and 1 mg/kg up to 50 mg in children
{{familytree | | | | | | | | I01 |-|-|'| | | |I01=<div style="float: left; text-align: left"> Secondary therapy after epinephrine '''(evidence not clear)''' <br> H1 antihistaminics: <br> ❑ Diphenhydramine IM or slow intravenous infusion - 25 to 50 mg in adults, and 1 mg/kg up to 50 mg in children
----
----
H2 antihistaminics: <br> ❑ Ranitidine - 1 mg/kg in adults, and 12.5 to 50 mg in children IV or IM </div>}}
H2 antihistaminics: <br> ❑ Ranitidine - 1 mg/kg in adults, and 12.5 to 50 mg in children IV or IM </div>}}
{{familytree | | | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | | | |!| | | | | | | | }}
{{familytree | | | | | | | | J01 | | | | | | |J01=<div style="float: left; text-align: left"> ❑ Observe the patient for biphasic anaphylaxis <br>
{{familytree | | | | | | | | J01 | | | | | | |J01=<div style="float: left; text-align: left"> ❑ Observe the patient for biphasic anaphylaxis <br>
: Total period of observation depends on <br> a) clinical condition <br> b) patients access to emergency care setting from home <br> ❑ Provide auto-injectable epinephrine and action plan for future events at discharge </div> }}
: Total period of observation depends on <br> a) clinical condition <br> b) patients access to emergency care setting from home <br>
❑ Provide auto-injectable epinephrine and action plan for future events at discharge </div> }}
{{familytree/end}}
{{familytree/end}}

Revision as of 14:28, 17 January 2014

Management

Shown below is an algorithm summarizing the approach to [[Anaphylaxis]].

 
 
 
 
 
 
 
Characterize the symptoms & signs:
Skin, subcutaneous tissue and mucosa:
❑ Flushing, itching, urticaria, angioedema, rash, piloerection
❑ Periorbital itching, erythema and edema; conjunctival erythema, tearing

Respiratory:
❑ Nasal itching, congestion, rhinorrhea, sneezing
❑ Throat itching and tightness, dysphonia, hoarseness, stridor, dry staccato cough
❑ Tachypnea, dyspnea,chest tightness, wheezing/bronchospasm
❑ Cyanosis
❑ Respiratory arrest


Gastrointenstinal:
❑ Pain, nausea, vomiting, diarrhea


Cardiovascular:
❑ Chest pain, tachycardia, palpitations
❑ Hypotension, feeling faint
❑ shock
❑ Cardiac arrest


Central nervous system:
❑ Anxiety, irritability
❑ Throbbing headache
❑ Altered vision and mental status
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Consider alternative diagnosis:
❑ Acute asthma
❑ Anxiety/Panic attack
❑ Syncope
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Remove patient from exposure/trigger
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Do all 3 simultaneously
❑ Call for help
Inject aqueous epinephrine (adrenaline) IM in the mid-anterolateral aspect of the thigh, 0.01 mg/kg of a 1:1,000 (1 mg/mL) solution
Maximum dose 0.5 mg (adult) or 0.3 mg (child)
Record the time of the dose and repeat it in 5-10 minutes, if needed or
❑ Intravenous epinephrine: In patients with hypotension/cardiorespiratory arrest and those not responding
1:100,000 solution of epinephrine (0.1 mg [1 ml of 1:1000] in 100 ml saline) intravenously by infusion pump at an initial rate of 30-100 ml/hr (5-15 mg/min)
Titrate based on clinical response or epinephrine side effects
❑ Place patient on back/comfortable position; elevate legs
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
Patient has one of the following?
❑ Respiratory distress
❑ Recieved repeated doses of epinephrine
❑ Asthma/other respiratory disease
❑ Co-existing cardiovascular disease
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Give high flow supplemental oxygen (6-8 L/min)
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient hypotensive despite epinephrine?
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
❑ Establish IV access
❑ Give 1-2 litres of 0.9% saline rapidly, 5-10 ml/Kg in first 5-10 mins
❑ Give vasopressors (dopamine) 400mg in 500ml of 5% dextrose at 2-20 mg/kg/min to maintain a target systolic BP > 90 mm Hg
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Secondary therapy after epinephrine (evidence not clear)
H1 antihistaminics:
❑ Diphenhydramine IM or slow intravenous infusion - 25 to 50 mg in adults, and 1 mg/kg up to 50 mg in children
H2 antihistaminics:
❑ Ranitidine - 1 mg/kg in adults, and 12.5 to 50 mg in children IV or IM
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
❑ Observe the patient for biphasic anaphylaxis
Total period of observation depends on
a) clinical condition
b) patients access to emergency care setting from home
❑ Provide auto-injectable epinephrine and action plan for future events at discharge